The total return over the past 12 months is -29.81% vs. +16.94% for the S&P 500. So far it's up -0.97% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | (29.81%) | (39.02%) | (44.03%) | (33.65%) | N/A | N/A |
| Total Return CAGR | (29.81%) | (39.02%) | (44.03%) | (33.65%) | N/A | N/A |
| Revenue CAGR | +43.96% | (68.80%) | (50.01%) | (15.38%) | N/A | N/A |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Cartesian Therapeutics, Inc. (RNAC)
| Year | Start price | End price | RNAC Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $7.21 | $7.14 | (0.97%) | +14.51% | (15.48%) |
| 2025 | $17.91 | $7.21 | (59.74%) | +17.72% | (77.46%) |
| 2024 | $20.68 | $17.91 | (13.39%) | +24.89% | (38.28%) |
| 2023 | $33.90 | $20.68 | (39.00%) | +26.19% | (65.19%) |
| 2022 | $97.80 | $33.90 | (65.34%) | (18.17%) | (47.17%) |
| 2021 | $90.90 | $97.80 | +7.59% | +28.74% | (21.15%) |
| 2020 | $71.40 | $90.90 | +27.31% | +18.37% | +8.94% |
| 2019 | $79.80 | $71.40 | (10.53%) | +31.22% | (41.75%) |
| 2018 | $294.30 | $79.80 | (72.88%) | (4.56%) | (68.32%) |
| 2017 | $514.50 | $294.30 | (42.80%) | +21.70% | (64.50%) |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
